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Approximately 40 trillion bacteria reside inside the
human intestine, meaning there are at least as many
cells of microbial origin as human origin [1]. While it
was once believed that bacteria and humans simply co-
existed in the same space, a wide body of evidence now
suggests that host–microbial communication is more
complex than ever imagined and the microbiome plays a
critical role in maintaining host homeostasis. The micro-
biome is also altered in multiple disease states, including
heart disease [2], cancer [3], and Clostridium difficile infec-
tion [4], with changes detectable in microbial composition,
number, diversity, and virulence compared to healthy con-
trols. While the majority of studies linking the microbiome
to disease are associative, there is increasing evidence that
the microbiome plays a crucial role in mediating the patho-
physiology of multiple acute and chronic illnesses.
The gut has long been hypothesized to be “the motor”
of multiple organ dysfunction syndrome (MODS) [5].
Notably, the microbiome is markedly altered in the in-
tensive care unit (ICU). A recent study sampling stool
from 115 critically ill patients revealed decreases in
Firmicutes and Bacteroidetes—bacteria that are prevalent
in the healthy intestine—with increases in opportunistic
Proteobacteria [6]. Although these findings cannot deter-
mine whether an altered microbiome functions as a
marker or mediator in the development of MODS, it
raises the question as to whether altering microbial ecol-
ogy and restoring diversity of the microbiome may be a
novel therapeutic strategy in critical illness.
Multiple methods to manipulate host bacteria have
been tried in patients, ranging from giving exogenous
bacteria in the form of probiotics to selecting out patho-
genic microbes via selective decontamination of the di-
gestive tract. While each of these strategies has shown
some clinical promise [7, 8], debatably the most effective
method of altering the microbiome in human disease is
fecal microbial transplantation (FMT). FMT is a proced-
ure where stool is collected from a healthy donor, fil-
tered for particulate matter, and the liquid portion given
to the patient via nasogastric tube or via the rectum [9].
FMT has been demonstrated to be significantly more ef-
fective in recurrent C. difficile infections than other
available therapies [10]. Treatment failures still occur,
however, which is not surprising given that we do not
yet fully understand the mechanisms responsible for the
success of FMT, nor do we know the optimal dose and
timing required for a successful transplant. Notably, vi-
ruses, fungi, viable colonocytes, immunoglobulins, me-
tabolites, and natural bacteriocins may be present in
FMT and impact outcomes [11, 12].
The literature on FMT in critical care is limited to a
single case report [11]. The barriers to utilizing FMT in
the ICU are significant. The impact of giving bacteria to
a patient with a markedly altered microbiome who likely
has a component of immunosuppression is unknown and
has inherent theoretical risks. In addition, the majority of
critically ill patients receive antibiotics at some point dur-
ing their ICU stay, and initiation or continuation of anti-
biotic therapy would be expected to markedly alter the
microbiome following FMT. As such, there must be a
commitment to stopping antibiotics both prior to and fol-
lowing FMT to allow the transplanted bacteria to take
hold and remodel the microbiome. This is a difficult
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action to take unless it is clear that a patient is not in-
fected, a clinical judgment which unfortunately is not al-
ways straightforward at the bedside.
Wei et al. recently reported the use of FMT in two
critically ill patients who developed sepsis during their
hospital course [13]. Each was successfully treated with
multiple antibiotics (which sterilized their cultures) but
was left with MODS and non-C. difficile diarrhea, refrac-
tory to standard medical management. Analysis of stool
from both patients demonstrated marked alterations in
the microbiome compared to healthy patients. The inves-
tigators concluded that the patients suffered from intes-
tinal dysbiosis not related to active infection and would
therefore be appropriate candidates for FMT. Antibiotics
were held, and three days later FMT was performed. Over
the 2–3 weeks following FMT, both patients had reso-
lution of their diarrhea and improvement in multiple
markers of inflammation such as interleukin-6, C reactive
protein, procalcitonin, and erythrocyte sedimentation rate.
Notably, the investigators followed the bacterial compos-
ition of the patients’ stool using 16s rRNA pyrosequenc-
ing, both immediately before and up to 20 days after
FMT. Following FMT, the composition and diversity in
both patients shifted toward that of the donor with in-
creasing Firmicutes and decreasing Proteobacteria.
Outside of antibiotics, supportive care remains the
mainstay of treatment in the ICU [14], and any new
therapy that has the capacity to cure a condition in crit-
ical illness is potentially exciting. However, the efficacy
seen with FMT in this study must be interpreted with
caution. First, while a rich and diverse intestinal micro-
biome is associated with health [15], this does not inher-
ently mean that the altered microbiome plays a causative
role in MODS or that restoration to a normal state in
critical illness is beneficial. In the cases presented here,
stool volume and inflammatory markers were already
decreasing prior to initiation of FMT, and it is possible
the patients would have recovered without receiving this
experimental therapy. Assuming FMT was indeed re-
sponsible for the ultimate improvement in patient
course, the degree of generalizability of the results pre-
sented is unclear, as with any case report. For instance, if
one imagines a clinical trial of FMT that mimics the pa-
tients studied, the entry criteria would be relatively
narrow—patients with MODS and dysbiosis-induced
non-infectious diarrhea who do not require antibiotics.
As such, FMT must be considered experimental in crit-
ical illness until rigorous trials are conducted. Nonethe-
less, the opportunity to manipulate our microbiome for
therapeutic benefit in the ICU represents a tantalizing
new direction in the future care of critically ill patients.
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